ABRs of 7-, 10-, and 14-d prophylaxis regimens
| . | Prophylaxis (group 1) across-treatment regimens . | Prophylaxis (group 1)* within-subject comparison . | ||||
|---|---|---|---|---|---|---|
| 7-d Regimen (N = 40) . | 10-d Regimen (N = 7) . | 14-d Regimen (N = 21) . | 7-d Regimen (N = 21) . | 14-d Regimen (N = 21) . | 7-d vs 14-d Regimen . | |
| AsBR | ||||||
| Median (IQR) | 0 (0, 0) | 0 (0, 0) | 0 (0, 1.0) | 0 (0, 0) | 0 (0, 1.0) | |
| Estimated rate† | 0.65 | 0.56 | 0.83 | 0.29 | 0.83 | 0.35 |
| 95% CI† | 0.37, 1.13 | 0.27, 1.17 | 0.38, 1.77 | 0.068, 1.198 | 0.385, 1.771 | 0.076, 1.575 |
| Mean difference (95% CI)‡ | −0.79 (−1.780, 0.197) | |||||
| Total ABR | ||||||
| Median (IQR) | 0 (0, 1.87) | 0 (0, 1.78) | 1.08 (0, 2.7) | 0 (0, 1.53) | 1.08 (0, 2.70) | |
| Estimated rate† | 1.58 | 1.69 | 1.61 | 0.69 | 1.61 | 0.43 |
| 95% CI† | 1.02, 2.44 | 0.87, 3.28 | 0.93, 2.80 | 0.296, 1.626 | 0.930, 2.801 | 0.162, 1.138 |
| Mean difference (95% CI)‡ | −1.25 (−2.562, 0.070) | |||||
| Joint ABR | ||||||
| Median (IQR) | 0 (0, 1.53) | 0 (0, 0.88) | 0 (0, 1.04) | 0 (0, 0) | 0 (0, 1.04) | |
| Estimated rate† | 1.13 | 0.92 | 1.11 | 0.41 | 1.11 | 0.36 |
| 95% CI† | 0.70, 1.84 | 0.41, 2.04 | 0.51, 2.41 | 0.141, 1.161 | 0.513, 2.414 | 0.111, 1.199 |
| Mean difference (95% CI)‡ | −0.97 (−2.197, 0.249) | |||||
| Treatment duration, wk | ||||||
| Median (IQR) | 38.4 (30.0, 82.3) | 34.3 (21.3, 58.6) | 55.1 (37.0, 63.6) | |||
| . | Prophylaxis (group 1) across-treatment regimens . | Prophylaxis (group 1)* within-subject comparison . | ||||
|---|---|---|---|---|---|---|
| 7-d Regimen (N = 40) . | 10-d Regimen (N = 7) . | 14-d Regimen (N = 21) . | 7-d Regimen (N = 21) . | 14-d Regimen (N = 21) . | 7-d vs 14-d Regimen . | |
| AsBR | ||||||
| Median (IQR) | 0 (0, 0) | 0 (0, 0) | 0 (0, 1.0) | 0 (0, 0) | 0 (0, 1.0) | |
| Estimated rate† | 0.65 | 0.56 | 0.83 | 0.29 | 0.83 | 0.35 |
| 95% CI† | 0.37, 1.13 | 0.27, 1.17 | 0.38, 1.77 | 0.068, 1.198 | 0.385, 1.771 | 0.076, 1.575 |
| Mean difference (95% CI)‡ | −0.79 (−1.780, 0.197) | |||||
| Total ABR | ||||||
| Median (IQR) | 0 (0, 1.87) | 0 (0, 1.78) | 1.08 (0, 2.7) | 0 (0, 1.53) | 1.08 (0, 2.70) | |
| Estimated rate† | 1.58 | 1.69 | 1.61 | 0.69 | 1.61 | 0.43 |
| 95% CI† | 1.02, 2.44 | 0.87, 3.28 | 0.93, 2.80 | 0.296, 1.626 | 0.930, 2.801 | 0.162, 1.138 |
| Mean difference (95% CI)‡ | −1.25 (−2.562, 0.070) | |||||
| Joint ABR | ||||||
| Median (IQR) | 0 (0, 1.53) | 0 (0, 0.88) | 0 (0, 1.04) | 0 (0, 0) | 0 (0, 1.04) | |
| Estimated rate† | 1.13 | 0.92 | 1.11 | 0.41 | 1.11 | 0.36 |
| 95% CI† | 0.70, 1.84 | 0.41, 2.04 | 0.51, 2.41 | 0.141, 1.161 | 0.513, 2.414 | 0.111, 1.199 |
| Mean difference (95% CI)‡ | −0.97 (−2.197, 0.249) | |||||
| Treatment duration, wk | ||||||
| Median (IQR) | 38.4 (30.0, 82.3) | 34.3 (21.3, 58.6) | 55.1 (37.0, 63.6) | |||
The median assigned doses for the 7-, 10-, and 14-d prophylaxis regimens were 40, 75, and 75 IU/kg, respectively.
Includes subjects with a minimum of 12 wk of treatment on both 7-d and 14-d prophylaxis.
The estimated rate was calculated assuming a Poisson distribution.
95% CI based on Student t test from matched pairs design.